Treats transient insomnia characterized. ANDA 220717, held by Umedica Labs Pvt. Zolpidem Tartrate.
As of Nov 16, 2026, ANDA 220717 (Zolpidem Tartrate), held by Umedica Labs Pvt, was first approved by FDA on May 12, 2026, with 0 approved supplements and 0 published complete response letters.
Zolpidem Tartrate Capsules are indicated for the short-term treatment of transient insomnia characterized by difficulties with sleep initiation in adults younger than 65 years of age.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 12, 2026 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Zolpidem Tartrate7.5MG · capsule;oral | Zolpidem Tartrate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters